Applications of Boc-(S)-3-Amino-4-(4-Iodo-Phenyl)-Butyric Acid in Industrial Manufacturing

Boc-(S)-3-Amino-4-(4-Iodo-Phenyl)-Butyric Acid serves as a vital intermediate for several specialized manufacturing pathways, primarily within pharmaceutical and research-driven synthesis sectors. As the direct manufacturer, we address core supply requirements for downstream processors who demand consistent quality, strict compliance, and reliable technical data supporting integration into multi-step routes. The following sections detail real applications across distinct industries.

1. Chiral Pharmaceutical Synthesis

This raw material frequently acts as a protected chiral building block in the multi-step synthesis of selective serotonin modulators, kinase inhibitors, and other active pharmaceutical ingredients (APIs). Many process chemists use it in asymmetric synthesis routes where precise stereochemistry is mandatory to ensure batch-to-batch reproducibility and regulatory approval. The Boc-protection safeguards amino functionality during coupling and deprotection steps, allowing complex molecule assembly with minimal side-products.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients (APIs)
• US FDA cGMP regulations (21 CFR Parts 210 and 211)
• European Pharmacopeia (Ph. Eur.) for raw material sourcing
• USP General Chapters on Excipients and Intermediates

Typical usage ratio

• 0.85 to 1.2 equivalents in asymmetric coupling steps, adjusted based on reaction yield and downstream conversion targets

Downstream process integration

• Incorporated during the condensation or peptide-coupling stage, usually post-initial intermediate preparation; Boc group removed in subsequent deprotection under acidic or catalytic conditions before final functionalization

Final product types

• Enantiopure serotonin inhibitors (small molecule APIs)
• Kinase modulator compounds
• Peptidomimetic drug candidates
• Early-phase clinical trial API supplies

2. Radiopharmaceutical Precursor Manufacturing

The presence of the iodo group on the phenyl ring allows this intermediate to function as a precursor in radioisotope labeling, particularly for PET and SPECT tracer design. Specialized facilities use the aromatic iodine for isotopic exchange reactions, introducing diagnostic isotopes such as ¹²³I, ¹²⁵I, or ¹³¹I in high-specific-activity environments. The chirality and Boc-protection are critical for synthesizing labeled compounds that meet both chemical and radiochemical purity requirements in clinical imaging agents.

Industry compliance standards

• US Pharmacopeia (USP) Chapter <825> for radiopharmaceutical compounding
• Guidance for Industry: CGMP for Phase 1 Investigational Drugs (FDA)
• European Medicines Agency (EMA) guidelines for Investigational Medicinal Products
• ISO 13485:2016 (medical device and diagnostic reagent production)

Typical usage ratio

• 1.0 equivalent as precursor charged relative to specific activity requirements and efficiency of isotope exchange reaction; ratios tuned according to target labeling yield

Downstream process integration

• Deployed at the radiolabeling stage after bulk intermediate preparations, where iodine-phenyl moiety undergoes direct isotopic labeling followed by rapid purification and formulation for injection or imaging agent kits

Final product types

• PET and SPECT imaging agents (e.g., radiolabeled neuroreceptor tracers)
• Single-dose radiodiagnostic kits
• Investigational radiopharmaceutical products for clinical research use
• Comparative preclinical imaging probe batches

3. Custom Peptide Analog Synthesis

In advanced peptide analog development, chemists rely on this intermediate to build non-natural amino acid residues with precise side-chain modifications. The Boc-protected amino group tolerates solid-phase and solution-phase peptide synthesis environments where orthogonal deprotection protocols demand precise control over side-chain protecting groups. Its incorporation enables tailored structure-activity relationship (SAR) exploration for both research and preclinical peptide drug candidates.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• GLP (Good Laboratory Practice) for non-clinical studies
• Peptide synthesis guidelines (FDA, EMA, JP) for clinical supply
• ISO 9001:2015 Quality Management Systems

Typical usage ratio

• 0.9 to 1.1 equivalents per peptide coupling cycle, adjusted based on resin loading, sequence length, and desired purity/yield

Downstream process integration

• Employed at the iterative chain-elongation stage during Fmoc/Boc solid-phase or solution-phase assembly; compatible with high-throughput parallel synthesis workflows and advanced purification steps

Final product types

• Custom peptide analogs for SAR and lead optimization
• Biotin- or fluorophore-labeled peptide reagents
• Peptidomimetic drug candidates for in vitro and in vivo assays
• Research-grade non-natural peptide batches

4. Fine Chemical and API Intermediate Supply

This compound serves as a core intermediate shipped under GMP or research-grade conditions to facilities specializing in API elaboration or bulk fine chemical transformations. The iodo-phenyl group supports downstream cross-coupling reactions (e.g., Suzuki, Sonogashira) to build more complex aromatic systems, while the optically active center enables chirality transfer in multi-step processes. Leading chemical companies integrate this material into multi-ton production campaigns for custom synthesis contracts as well as boutique API development.

Industry compliance standards

• Current Good Manufacturing Practice (cGMPs) – ICH Q7 for intermediates
• Global regulatory filings (DMFs for the US, CEP for Europe)
• ISO 14001:2015 for environmental management
• Hazardous chemical transport and storage rules (UN/ADR/IMDG)

Typical usage ratio

• Varies from 1.0 to 1.5 equivalents depending on targeted coupling efficiency and downstream stoichiometry; manufacturers set ratios after pilot reaction optimization

Downstream process integration

• Introduced following initial building block assembly, then transformed via Pd-catalyzed cross-coupling or amide-forming reactions, with rigorous in-process analytical controls to verify conversion and product identity

Final product types

• Advanced chiral pharmaceutical intermediates
• Specialty heterocyclic compounds
• Custom fine chemicals for contract manufacturing
• API candidates for late-stage process scale-up